FDA Expands Label of Oral HIV Drug to Newborns

ViiV wins US approval for HIV treatment in newborn babies

The US FDA has green lit ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 in children weighing at least 2 kg.

FDA Expands Label of Oral HIV Drug to Newborns

Dolutegravir is already approved as combination therapy in adults and older children

Newborns with HIV Can Now Get a Second Generation Antiviral from Birth Under a Newly Expanded Federal Label

The FDA extended Tivicay PD to newborns from birth weighing at least 2 kg, closing a long-standing gap in infant HIV treatment options.

ViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy

The US FDA has approved ViiV Healthcare’s Tivicay PD, for use with other antiretroviral agents in paediatric patients with HIV-1 who weigh at least 2 kg.The post ViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy appeared first on Hospital Management.